# Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy

> **NCT03177083** · PHASE4 · COMPLETED · sponsor: **Biogen** · enrollment: 80 (actual)

## Conditions studied

- Relapsing Remitting Multiple Sclerosis

## Interventions

- **DRUG:** peginterferon beta-1a
- **DRUG:** interferon beta-1a
- **DRUG:** interferon beta-1b

## Key facts

- **NCT ID:** NCT03177083
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-30
- **Primary completion:** 2020-10-26
- **Final completion:** 2020-10-26
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2020-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03177083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03177083, "Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03177083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*